Clinical trial DALY 2-EU
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation (M-2020-371)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Miltenyi Biomedicine GmbH |
| EudraCT Identifier | 2020-003908-14 |
| Inclusion criteria | - Histologically proven DLBCL and associated subtypes- Relapsed or refractory disease after first-line chemoimmunotherapy- Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regime |
| Last update |